• Purity

  >95%, by SDS-PAGE under reducing conditions and visualized by silver stain

• Endotoxin Level

  <0.10 EU per 1 μg of the protein by the LAL method.  

• Activity

  Measured by its binding ability in a functional ELISA.

  When Recombinant Human (rh) EphA7 Fc Chimera is coated at 2 μg/mL (100 μL/well), the concentration of biotinylayed rhEphrin-A4 Fc Chimera that produces 50% of the optimal binding response is found to be approximately 1.5 ‑ 6 ng/mL.

• Source

  Mouse myeloma cell line, NS0-derived

  Human EphA7 (Met1 - Val555) Accession # NP_004431	IEGRMD	Human IgG1 (Pro100 - Lys330)
  N-terminus		C-terminus

• Accession #

• N-terminal Sequence    
  Analysis

  Ala30 & Gln28, predicted, not obtained, sequencing might be blocked

• Structure / Form

  Disulfide-linked homodimer

• Predicted Molecular Mass

  85.7 kDa

• SDS-PAGE

  95-105 kDa, reducing conditions

Background: EphA7

EphA7, also known as Mdk1, Hek11, Ehk3, Ebk, and Cek11, is a 115 ‑ 120 kDa glycosylated member of the Eph family of transmembrane receptor tyrosine kinases (1, 2). The A and B classes of Eph proteins are distinguished by Ephrin ligand binding preference but have a common structural organization. EphA7 preferentially binds to and is activated by Ephrin‑A1, ‑A2, ‑A3, ‑A4, and ‑A5 (3 ‑ 6). Eph‑Ephrin interactions are widely involved in the regulation of cell migration, tissue morphogenesis, and cancer progression. The 532 amino acid (aa) extracellular domain (ECD) of human EphA7 contains an N‑terminal Ephrin binding region, a cysteine‑rich region, and two fibronectin type III domains (FnIII). The 421 aa cytoplasmic domain contains the tyrosine kinase domain and a sterile alpha motif (SAM) (7). Within the ECD, human EphA7 shares 98% aa sequence identity with mouse and rat EphA7. Alternate splicing generates secreted isoforms of human EphA7 that are truncated either before or following the first FnIII domain (7, 8). In mouse, EphA7 is expressed in discrete regions of the developing and adult neocortex (4, 9 ‑ 12), Purkinje layer of the cerebellum (10), limbic system (4, 9, 11, 12), visual and auditory systems (10, 11, 13), and the peripheral sensory nervous system (10, 11). EphA7 functions as a repulsive guidance molecule during the targeting of retinal axons to the superior colliculus  and of neocortical axons to the thalamus (4, 9, 13). EphA7 is also expressed in mesenchymal cells along routes of axon innervation during limb development (14). EphA7 ligands are expressed in a complementary pattern during embryogenesis (3, 9, 13, 14). EphA7 is selectively expressed in early stages of the B cell lineage, and a 50 kDa secreted form is produced by mature peripheral B and T cells (6, 15). This isoform is also expressed in human lung carcinoma (8). EphA7 can be up or down‑regulated in a variety of human cancers (6, 16, 17).

• References:

1. Pasquale, E.B. (2005) Nat. Rev. Mol. Cell Biol. 6:462.

2. Merlos-Suarez, A. and E. Batlle (2008) Curr. Opin. Cell Biol. 20:194.

3. Ciossek, T. and A. Ullrich (1997) Oncogene 14:35.

4. Miller, K. et al. (2006) J. Comp. Neurol. 496:627.

5. Gale, N.W. et al. (1996) Neuron 17:9.

6. Dawson, D.W. et al. (2007) Oncogene 26:4243.

7. Fox, G.M. et al. (1995) Oncogene 10:897.

8. Tsuboi, M. et al. (2010) Int. J. Oncol. 36:635.

9. Torii, M. and P. Levitt (2005) Neuron 48:563.

10. Ciossek, T. et al. (1995) Oncogene 9:97.

11. Mori, T. et al. (1995) Mol. Brain Res. 34:154.

12. Ciossek, T. et al. (1999) Mol. Brain Res. 74:231.

13. Rashid, T. et al. (2005) Neuron 47:57.

14. Araujo, M. et al. (1998) Development 125:4195.

15. Aasheim, H.-C. et al. (1997) Blood 90:3613.

16. Hafner, C. et al. (2004) Clin. Chem. 3:490.

17. Wang, J. et al. (2007) Hum. Pathol. 38:1649.

• Long Name:

  Eph Receptor A7

• Entrez Gene IDs:

  2045 (Human); 13841 (Mouse)

• Alternate Names:

  Cek11; Ebk; EC 2.7.10; EC 2.7.10.1; Ehk3; EHK-3; EK11; EPH homology kinase 3; Eph homology kinase-3; EPH receptor A7; EphA7; EPH-like kinase 11; ephrin type-A receptor 7; Hek11; Mdk1; receptor protein-tyrosine kinase HEK11; tyrosine-protein kinase receptor EHK-3